Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation

Authors Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Received 6 November 2016

Accepted for publication 6 January 2017

Published 8 March 2017 Volume 2017:13 Pages 287—297

DOI https://doi.org/10.2147/TCRM.S126869

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Rasmus Rivinius,1 Matthias Helmschrott,1 Arjang Ruhparwar,2 Christian Erbel,1 Christian A Gleissner,1 Fabrice F Darche,1 Dierk Thomas,1 Tom Bruckner,3 Hugo A Katus,1 Andreas O Doesch1

1Department of Cardiology, Angiology and Pneumology, 2Department of Cardiac Surgery, Heidelberg University Hospital, 3Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Purpose: Early posttransplant atrial fibrillation (AF) has been associated with worse clinical outcomes after heart transplantation (HTX). The type of surgical technique may constitute a relevant risk factor for AF.
Patients and methods: This retrospective single-center study included 530 adult patients. Patients were stratified by surgical technique (biatrial, bicaval, or total orthotopic HTX) and early posttransplant heart rhythm (AF or sinus rhythm). Univariate and multivariate analyses were performed to evaluate risk factors for AF.
Results: A total of 161 patients received biatrial HTX (30.4%), 115 bicaval HTX (21.7%), and 254 total orthotopic HTX (47.9%). Sixty-one of 530 patients developed early posttransplant AF (11.5%). Patients with AF showed a statistically inferior 5-year survival compared to those with sinus rhythm (P<0.0001). Total orthotopic HTX had the lowest rate of AF (total orthotopic HTX [6.3%], bicaval HTX [14.8%], biatrial HTX [17.4%], P=0.0012). Multivariate analysis showed pretransplant valvular heart disease (P=0.0372), posttransplant enlarged left atrium (P=0.0066), posttransplant mitral regurgitation (P=0.0370), and non-total orthotopic HTX (P=0.0112) as risk factors for AF.
Conclusion: Early posttransplant AF was associated with increased mortality (P<0.0001). Total orthotopic HTX showed the lowest rate of AF compared to biatrial or bicaval HTX (P=0.0012).

Keywords: atrial fibrillation, biatrial heart transplantation, bicaval heart transplantation, mortality, surgical technique, total orthotopic heart transplantation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality

Rivinius R, Helmschrott M, Ruhparwar A, Rahm AK, Darche FF, Thomas D, Bruckner T, Ehlermann P, Katus HA, Doesch AO

Therapeutics and Clinical Risk Management 2017, 13:1399-1407

Published Date: 13 October 2017

Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2017, 11:1827-1837

Published Date: 19 June 2017

Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy

Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2017, 11:1673-1680

Published Date: 7 June 2017

Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2016, 10:677-686

Published Date: 16 February 2016

Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation

Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:1217-1224

Published Date: 24 February 2015

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2015, 9:93-102

Published Date: 17 December 2014

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen

Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO

Drug Design, Development and Therapy 2014, 8:1307-1314

Published Date: 9 September 2014

Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions

Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C

Drug Design, Development and Therapy 2014, 8:447-457

Published Date: 12 May 2014

Conversion to generic cyclosporine A in stable chronic patients after heart transplantation

Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:1421-1426

Published Date: 28 November 2013

Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study

Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA

Drug Design, Development and Therapy 2013, 7:1323-1328

Published Date: 5 November 2013

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation

Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2013, 7:1253-1258

Published Date: 21 October 2013

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO

Drug Design, Development and Therapy 2013, 7:297-303

Published Date: 8 April 2013

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA

Drug Design, Development and Therapy 2012, 6:289-295

Published Date: 12 October 2012